Novozymes A/S
OTC:NVZMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novozymes A/S
OTC:NVZMY
|
DK |
|
A
|
ACS Actividades de Construccion y Servicios SA
XMUN:OCI1
|
ES |
|
B
|
BP PLC
BMV:BPN
|
UK |
|
Yangarra Resources Ltd
TSX:YGR
|
CA |
|
Gran Tierra Energy Inc
TSX:GTE
|
CA |
|
B
|
Bristol-Myers Squibb Co
DUS:BRM
|
US |
|
D
|
Dunelm Group PLC
OTC:DNLMY
|
UK |
|
Selamat Sempurna Tbk PT
IDX:SMSM
|
ID |
|
Danone SA
OTC:GPDNF
|
FR |
|
J
|
Jabil Inc
DUS:JBL
|
US |
|
B
|
BlackBerry Ltd
F:RI1
|
CA |
|
Oversea-Chinese Banking Corporation Ltd
F:OCBB
|
SG |
Wall St Price Targets
NVZMY Price Targets Summary
Novozymes A/S
According to Wall Street analysts, the average 1-year price target for
NVZMY is 72.93 USD with a low forecast of 59.04 USD and a high forecast of 89.16 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NVZMY's stock price target?
Price Target
72.93
USD
According to Wall Street analysts, the average 1-year price target for
NVZMY is 72.93 USD with a low forecast of 59.04 USD and a high forecast of 89.16 USD.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.